The Week in Review: May 25 – June 1, 2018

Friday, June 1, 2018 News Recap: HCV: Large Study Confirms DAAs Protect Against HCC When Sustained Viral Response Achieved. Patients with hepatitis C virus who are successfully treated with direct-acting antiviral agents experience a dramatic reduction in their risk for liver cancer, new data show. However, the decrease is much lower for those diagnosed with cirrhosis before starting a DAA. HCV Guidance Updated for Screening and Treating Key Popu...

Hepatitis C Virus Infection Linked to Gut Dysbiosis

Hepatitis C virus (HCV) infection is associated with gut dysbiosis, and the microbiome transition could be a biological indicator of chronic hepatitis C progression in patients with mild liver disease, according to a study published in Clinical Infectious Diseases. The gut microbiota is closely associated with the progression of liver diseases, and previous studies indicate that gut dysbiosis affects chronic liver disease, including the most severe forms

The Week in Review: January 19 – January 26, 2018

Friday, January 26, 2018 News Recap: Research and Discoveries: Growing Evidence Shows Hepatitis C Intersects With Other Diseases. As many as three-quarters of individuals with hepatitis C virus (HCV) experience disorders related to the virus beyond the impact on their livers, the National Viral Hepatitis Roundtable estimates. HCV-related kidney disease, depression, skin disorders, lymphoma and other conditions can seriously impact a patient, even wi...

Association Between HBV, HCV and Age-Related Cataracts

According to research in Scientific Reports, the occurrence of age-related cataracts is associated with hepatitis B virus (HBV) and hepatitis C virus C (HCV) infection. Liver dysfunction is a known significant risk factor for cataract formation, and the liver-damaging effects of HBV and HCV are hypothesised to play a role as well. To test this, associations between hepatitis and cataracts were tested along with any mediation of these associations by the l

The Week in Review: August 11 – August 18, 2017

Friday, August 18, 2017 Canada Great news in Canada. Two new drug regimens have been approved:  Vosevi from Gilead is a pangenotypic for retreatment of those who have failed previous DAA therapy Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection. And MAVIRET from AbbVie is the first and only 8-week, pan-genotypic treatment for hepatit...

Hepatitis C Virus Infection and Cardiovascular Disease Risk

Patients with HCV infection have a higher risk for carotid atherosclerosis and cerebrocardiovascular events. Hepatitis C virus (HCV) infection is a common cause of chronic liver disease worldwide and is associated with greater mortality compared with that in the general population or even mortality associated with HIV infection. Although liver disease and liver cirrhosis account for the bulk of HCV-related disease burden and deaths, it is becoming increas

Cardiovascular Disease Risk Is Higher for People with Hepatitis C

This is from January 2016 but well worth the reprint.  We are noting more and more people being cured of HCV only to have heart attacks and strokes.  Further, some studies have shown that some DAAs affect LDL levels (bad cholesterol) such that for 6-months post treatment LDL levels can be higher than normal and this is a stroke risk.  Studies from Japan and Egypt have noted that sofosbuvir-containing treatments may have caused strokes – CDM. People with h

The Week in Review: Jan 27, 2017 – Feb 3, 2017

Friday, February 3, 2017 News Recap Hepatitis C and Rheumatic, Kidney & Heart Disease As you may remember there have been quite a few news items over the past few months about the extrahepatic effects of hepatitis C, which is more and more coming to be recognized as a multi-organ disease.  Not only is the hepatitis C virus (HCV) the cause of liver diseases in up to 170 million people worldwide, it also has many extrahepatic disease manifestation...

Direct-Acting Antivirals for HCV-Associated Rheumatic Diseases

Not only is the hepatitis C virus (HCV) the cause of liver diseases in up to 170 million people worldwide, it also has many extrahepatic disease manifestations. These include rheumatic, hematologic, cardiovascular diseases. In a review article published in Rheumatic Disease Clinics of North America, Patrice Cacoub, MD, from the Pitié-Salpêtrière University Hospital, Paris, France, and colleagues discuss the main rheumatologic diseases associated with chro